Foghorn Therapeutics

FHTX Lead: Phase 1 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-11

Catalyst timeline

Selective ARID1B degrader readout2026Selective ARID1B degrader readout, 2026, notable
Selective CBP degrader corporate update2026Selective CBP degrader corporate update, 2026, routine
Selective EP300 degrader corporate update2026Selective EP300 degrader corporate update, 2026, routine
inobrodib CellCentric trial startmid-2026inobrodib CellCentric trial start, mid-2026, routine
Lilly collaboration FDA decisionDec 2026Lilly collaboration FDA decision, Dec 2026, routine
Selective EP300 degrader IND filing2027Selective EP300 degrader IND filing, 2027, notable
Undisclosed I&I program IND filing2027Undisclosed I&I program IND filing, 2027, routine
Company cash runway guidance update1H 2028Company cash runway guidance update, 1H 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

FHD-909

Small Molecule Target: SMARCA2

Non-Small Cell Lung Cancer Phase 1 oral Eli Lilly and Company

CBPd-171

FHT-171

Small Molecule Target: CBP

Breast Cancer Preclinical subcutaneous

novel oral small molecule

Undisclosed indication oral

selective EP300 degrader

Target: EP300

Technology platforms

Gene Traffic Control · Eli Lilly and Company

Proprietary platform providing integrated and mechanistic understanding of the chromatin regulatory system; used to identify, validate and drug targets within this system; focus areas include oncology and immunology/inflammation. Enables discovery of small molecules including protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors targeting SMARCA2 (BRM), CBP, EP300, ARID1B and other undisclosed targets.

Targets: SMARCA2, CBP, EP300, ARID1B, BRM

Gene Traffic Control Platform · Eli Lilly

Chromatin biology-based drug discovery platform leveraging deep mechanistic understanding of chromatin regulatory system to identify and develop selective small molecules and degraders targeting chromatin remodeling complexes, transcription factors, and other chromatin binding proteins; focus areas include oncology and immunology/inflammation

Targets: SMARCA2, ARID1B, CBP, EP300

Gene Traffic Control · Lilly

Chromatin regulatory system platform for systematically studying, identifying, and validating drug targets within chromatin biology; focus areas include oncology and immunology & inflammation; enables discovery of inhibitors, degraders, molecular glues, RIPTACs, and induced proximity molecules

Targets: SMARCA2, SMARCA4, EP300, CBP, ARID1B

Biotech Distilled coverage (2)

2026-08-07 UPDATE: Foghorn Therapeutics (FHTX) - The CRO Ate Their Homework 🔒 Paid
2026-07-08 Foghorn Therapeutics (FHTX) — Scientific Deep Dive for FHD-909 and the Chromatin Degrader Pipeline 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.